Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uhi Toh

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Experimental and Therapeutic Medicine|November 14, 2013
Treatment outcome in patients with stage III breast cancer treated with neoadjuvant chemotherapyRyuji Takahashi, Uhi Toh, Nobutaka Iwakuma, et al.
Pathology International|January 9, 2010
Clinicocytopathology of breast cancers with a ring-like appearance on ultrasonography and/or magnetic resonance imagingRin Yamaguchi, Maki Tanaka, Toshiro Yokoyama, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 17, 2026
[A Case of Hormone Receptor-Positive, HER2-Negative Metastatic Recurrent Breast Cancer Successfully Treated with Capivasertib and Fulvestrant in Late-Line Therapy]Masami Hattori, Hitomi Mori, Torakichi Shingo, et al.
Journal of Cellular Biochemistry|February 24, 2012
Tricin inhibits proliferation of human hepatic stellate cells in vitro by blocking tyrosine phosphorylation of PDGF receptor and its signaling pathwaysNaoko Seki, Uhi Toh, Koji Kawaguchi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 19, 2010
[A case of breast meningeal carcinomatosis caused by trastuzumab treatment as adjuvant chemotherapy]Hiroki Takahashi, Teruhiko Fujii, Yuka Inoue, et al.
Cancer Science|July 28, 2015
Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 alleleShinjiro Sakamoto, Satoko Matsueda, Shinzo Takamori, et al.
Breast Cancer Research : BCR|July 5, 2014
Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patientsRyuji Takahashi, Uhi Toh, Nobutaka Iwakuma, et al.
Cancer Research|November 24, 2016
Breast Cancer Resistance to Antiestrogens Is Enhanced by Increased ER Degradation and ERBB2 ExpressionTomohiro Shibata, Kosuke Watari, Hiroto Izumi, et al.
Cancer Science|February 9, 2017
Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11<sup>+</sup> or -A33<sup>+</sup> alleleShinjiro Sakamoto, Satoko Matsueda, Shinzo Takamori, et al.
Breast Cancer Research and Treatment|March 31, 2023
Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)Kenichi Watanabe, Naoki Niikura, Yuichiro Kikawa, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Experimental and Therapeutic Medicine|November 14, 2013
Treatment outcome in patients with stage III breast cancer treated with neoadjuvant chemotherapyRyuji Takahashi, Uhi Toh, Nobutaka Iwakuma, et al.
Pathology International|January 9, 2010
Clinicocytopathology of breast cancers with a ring-like appearance on ultrasonography and/or magnetic resonance imagingRin Yamaguchi, Maki Tanaka, Toshiro Yokoyama, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 17, 2026
[A Case of Hormone Receptor-Positive, HER2-Negative Metastatic Recurrent Breast Cancer Successfully Treated with Capivasertib and Fulvestrant in Late-Line Therapy]Masami Hattori, Hitomi Mori, Torakichi Shingo, et al.
Journal of Cellular Biochemistry|February 24, 2012
Tricin inhibits proliferation of human hepatic stellate cells in vitro by blocking tyrosine phosphorylation of PDGF receptor and its signaling pathwaysNaoko Seki, Uhi Toh, Koji Kawaguchi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 19, 2010
[A case of breast meningeal carcinomatosis caused by trastuzumab treatment as adjuvant chemotherapy]Hiroki Takahashi, Teruhiko Fujii, Yuka Inoue, et al.
Cancer Science|July 28, 2015
Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 alleleShinjiro Sakamoto, Satoko Matsueda, Shinzo Takamori, et al.
Breast Cancer Research : BCR|July 5, 2014
Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patientsRyuji Takahashi, Uhi Toh, Nobutaka Iwakuma, et al.
Cancer Research|November 24, 2016
Breast Cancer Resistance to Antiestrogens Is Enhanced by Increased ER Degradation and ERBB2 ExpressionTomohiro Shibata, Kosuke Watari, Hiroto Izumi, et al.
Cancer Science|February 9, 2017
Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11<sup>+</sup> or -A33<sup>+</sup> alleleShinjiro Sakamoto, Satoko Matsueda, Shinzo Takamori, et al.
Breast Cancer Research and Treatment|March 31, 2023
Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)Kenichi Watanabe, Naoki Niikura, Yuichiro Kikawa, et al.
Pageof 7